Evidence map›Paper›PMID 40841501›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

Enhanced contrast in FAP-targeting PET imaging with

Jacopo Millul, Tais Basaco Bernabeu, Raghuvir H Gaonkar, Francesco De Rose, Leila Jaafar-Thiel, Gary A Ulaner, Rosalba Mansi, Melpomeni Fani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Positron emission tomography in sarcomas].Radiologie (Heidelberg, Germany) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jacopo MillulDivision of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland.
Tais Basaco BernabeuDivision of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland.
Raghuvir H GaonkarDivision of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland.
Francesco De RoseNuclidium AG, Basel, Switzerland.
Leila Jaafar-ThielNuclidium AG, Basel, Switzerland.
Gary A UlanerMolecular Imaging and Therapy, Hoag Family Cancer Institute, Irvine, CA, USA.
Rosalba MansiDivision of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland.
Melpomeni FaniDivision of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland. melpomeni.fani@usb.ch.ORCID http://orcid.org/0000-0002-9309-1604

Funding

Innosuisse - Schweizerische Agentur für Innovationsförderung 100.918 IP-LS
6 · The paper itself

Abstract

backgroundFibroblast activation protein (FAP)-targeting radioligands have gained attention for the ability to image multiple tumor types. Current FAP-targeting radioligands are labeled with

resultsFour Kalios ligands were synthesized and radiolabeled with [

conclusionsKalios ligands represent a new class of FAP-targeting

Indexed as

61/67Cu theranostics61CuFAPIFibroblast activation protein-α (FAP)Late time-point imagingPET

Identifiers

PMID40841501
PMCPMC12370594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.